Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their experience with scalp micropigmentation (SMP) after one year. They discussed using Minoxidil, finasteride, and RU58841 as treatments for hair loss.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The user experienced sensitivity and side effects from finasteride and Saw Palmetto, leading to swollen and sensitive breasts, and decided to stop finasteride after two weeks. They are now trying Saw Palmetto, Biotin, and Ashwagandha, while others in the conversation discuss their own experiences with hair loss treatments like minoxidil and finasteride.

The user reports significant hair regrowth using a topical solution of 5% minoxidil and 0.1% finasteride twice daily, along with derma rolling twice a week. They have not experienced shedding and are optimistic about continued hair growth.

The conversation discusses whether baby hairs observed after using finasteride and minoxidil will grow into terminal hairs, with mixed experiences and opinions shared on the effectiveness of these treatments for hair regrowth. Some users report positive results, while others are skeptical about the potential for significant change.

People are discussing making their own PP405 for hair loss treatment using JLX069 and DMSO. There is skepticism about the safety and effectiveness of this homemade solution, with some users expressing concerns about potential risks.

The conversation discusses using a blend of coconut, argan, and rosemary oils for hair growth, along with microneedling and supplements like biotin and collagen. The user is hesitant to use Minoxidil or finasteride and is exploring natural alternatives for thinning hair.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

A 25-year-old male shared his 3-month progress using oral minoxidil, finasteride, and biotin for hair growth, reporting positive results and minimal side effects, such as slightly reduced libido. He plans to continue treatment and possibly add microneedling, with hopes of further improvement and potential hair transplant if needed.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.